Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  GlaxoSmithKline    GSK   GB0009252882

GLAXOSMITHKLINE

(GSK)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Vectura, Sandoz win ruling on inhaler packaging case against GSK

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/04/2019 | 12:35pm EDT
FILE PHOTO: The GSK logo is seen on top of GSK Asia House in Singapore

(Reuters) - Vectura Group said on Friday a British court had ruled in its favour on the packaging of a generic version of an inhaler made by bigger rival GlaxoSmithKline.

Vectura said the court dismissed all GSK claims related to the packaging of AirFluSal Forspiro, which it developed in partnership with Sandoz, owned by Swiss drugmaker Novartis, as a branded version of GSK's asthma inhaler, Seretide Accuhaler.

GSK, with which Vectura has partnerships, said it was "disappointed" with the court decision and will "consider its next steps".

Sandoz launched AirFluSal Forspiro in late 2015, following which GSK filed a legal claim that Sandoz had used shades of purple similar to Seretide's packaging to pass off AirFluSal Forspiro as being related to GSK's product.

"Our issue was simply with the colour of the device itself and its similarity to GSK’s Advair/Seretide," a GSK spokesman said, adding that the company was not opposed to a new entrant in the market.

Forspiro is a dry powder inhaler developed by Vectura andlicensed to Sandoz for use with the AirFluSal product.

Seretide is a combination of two active ingredients that make it easier to breathe and is sold by GSK in the UK in two forms http://public.gsk.co.uk/products/seretide/i-am-a-patient.html, one of which is the Seretide Accuhaler, which delivers the drug as a dry powder.

Vectura shares rose as much as 2.4% after the announcement.

In May, a jury found that one of Vectura's U.S. patents was infringed by the sale of three of GSK's Ellipta products in the United States and Vectura was awarded $89.7 million (£72.73 million) in damages.

(Reporting by Pushkala Aripaka in Bengaluru; Editing by Arun Koyyur and Deepa Babington)

Stocks mentioned in the article
ChangeLast1st jan.
GLAXOSMITHKLINE 0.23% 1632.2 Delayed Quote.9.72%
NOVARTIS 0.31% 86.7 Delayed Quote.16.30%
VECTURA GROUP PLC 0.24% 86.86 Delayed Quote.23.79%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GLAXOSMITHKLINE
10/16Factbox - How are businesses preparing for a 'no-deal Brexit'?
RE
10/15EUROPE MARKETS: European Stocks Surge To Best Level In 16 Months On Brexit Op..
DJ
10/15LONDON MARKETS: Pound Surges On Report Of Possible Draft Brexit Deal
DJ
10/12LONDON MARKETS: Brexit Hopes Sends British Pound To Highest Level Of Johnson ..
DJ
10/09UK accounting watchdog to get 80 more 'teeth'
RE
10/08GSK recalls popular heartburn drug Zantac globally after cancer scare
RE
10/08Glaxo Links Up with US Biotech to Target Solid Tumors with Cell Therapy
DJ
10/08GLAXOSMITHKLINE : Zantac - MHRA drug alert issued as GlaxoSmithKline recalls all..
AQ
10/07LONDON STOCK EXCHANGE : Trade hopes lift FTSE 100, SIG drags down mid-caps
RE
10/04Vectura, Sandoz win ruling on inhaler packaging case against GSK
RE
More news
Financials (GBP)
Sales 2019 32 780 M
EBIT 2019 8 862 M
Net income 2019 4 818 M
Debt 2019 23 845 M
Yield 2019 4,89%
P/E ratio 2019 16,8x
P/E ratio 2020 16,1x
EV / Sales2019 3,20x
EV / Sales2020 2,96x
Capitalization 80 971 M
Chart GLAXOSMITHKLINE
Duration : Period :
GlaxoSmithKline Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 1 782,68  GBp
Last Close Price 1 636,20  GBp
Spread / Highest target 34,5%
Spread / Average Target 8,95%
Spread / Lowest Target -7,71%
EPS Revisions
Managers
NameTitle
Emma Walmsley Chief Executive Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Iain James Mackay Chief Financial Officer & Executive Director
Karenann K. Terrell Chief Technology & Digital Officer
Hal V. Barron Executive Director & Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
GLAXOSMITHKLINE9.72%103 916
JOHNSON & JOHNSON2.94%356 736
ROCHE HOLDING AG17.38%245 163
MERCK AND COMPANY10.52%216 224
PFIZER-16.75%200 998
NOVARTIS16.30%198 756